Form 4: OptiNose Executive Anthony J. Krick Reports Stock and Option Awards

Chief Accounting Officer Anthony J. Krick received restricted stock units and stock options from OptiNose, Inc. on February 28, 2024.

Summary

• Anthony J. Krick, Chief Accounting Officer of OptiNose, Inc., reported changes in beneficial ownership of securities.
• On February 28, 2024, Krick was granted 112,500 restricted stock units (RSUs) and an option to purchase 56,250 shares of common stock.
• The RSUs vest over a four-year period, with 25% vesting on February 28, 2025, and the remainder vesting in equal quarterly installments.
• Full vesting of the RSUs is contingent upon meeting certain performance criteria related to OptiNose's net revenue and operating profit, as well as continued service.
• The stock options also vest over a four-year period, with 25% vesting on February 28, 2025, and the remainder vesting in equal monthly installments.
• The exercise price of the stock options is $1.815 per share, and they expire on February 28, 2034.
• Following these transactions, Krick directly owns 146,333 shares of OptiNose common stock and options to purchase 56,250 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The document reports standard executive compensation practices, which are generally viewed as a positive sign of aligning management interests with shareholders. The performance-based vesting adds a layer of potential upside.

Positives

• The grant of RSUs and stock options to a key executive like the Chief Accounting Officer suggests an incentive to align their interests with the company's long-term success.
• The vesting schedules, tied to both time and performance, could motivate the executive to contribute to OptiNose's financial goals.

Risks

• The vesting of RSUs is contingent on meeting certain performance criteria, which introduces uncertainty regarding the actual value the executive will ultimately receive.
• If the performance criteria are not met, the executive may not fully vest in the RSUs, potentially impacting their motivation or retention.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting of RSUs is tied to the company's future net revenue and operating profit.

Industry Context

This type of equity compensation is common in the pharmaceutical industry to attract and retain key personnel and align their interests with shareholder value.

Comparison to Industry Standards

• Equity grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Regeneron, and Vertex Pharmaceuticals routinely grant stock options and restricted stock units to their executives.
• The vesting schedules and performance-based conditions are also typical, designed to incentivize long-term value creation.
• The specific terms of the grants, such as the exercise price and vesting percentages, would need to be compared to peer companies to assess their competitiveness.

Stakeholder Impact

• Shareholders: The equity grants could align executive interests with shareholder value creation.
• Employees: The grants could serve as a motivating factor for other employees, knowing that management is incentivized to improve company performance.

Key Dates